Analyst Ratings For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Today, Stifel Nicolaus initiated coverage on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a Hold with a price target of $17.00.
There are 8 Buy Ratings, 4 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is Buy with a consensus target price of $43.5455 per share, a potential 213.05% upside.
Some recent analyst ratings include
- 8/7/2018-Stifel Nicolaus initiated coverage with a Hold rating.
- 8/6/2018-Piper Jaffray Companies was Downgraded by analysts at Piper Jaffray Companies from a “Overweight ” rating to a ” Neutral” rating. They now have a $19.00 price target on the stock.
- 5/16/2018-HC Wainwright Reiterated Rating of Buy.
- 11/7/2017-Cowen Reiterated Rating of Buy.
- 10/12/2017-Jefferies Financial Group Reiterated Rating of Buy.
- 10/9/2017-Leerink Swann Reiterated Rating of Market Perform.
Recent Insider Trading Activity For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has insider ownership of 23.28% and institutional ownership of 96.72%.
- On 3/1/2018 Daniel B Soland, Director, bought 7,000 with an average share price of $23.91 per share and the total transaction amounting to $167,370.00.
- On 1/29/2018 Glenn Baity, EVP, sold 36,558 with an average share price of $32.39 per share and the total transaction amounting to $1,184,113.62.
- On 1/2/2018 Glenn Baity, EVP, sold 74,321 with an average share price of $30.14 per share and the total transaction amounting to $2,240,034.94.
- On 1/2/2018 Laura Brege, Director, sold 25,000 with an average share price of $30.06 per share and the total transaction amounting to $751,500.00.
- On 10/5/2017 Glenn Baity, EVP, sold 37,500 with an average share price of $40.91 per share and the total transaction amounting to $1,534,125.00.
- On 8/30/2017 Glenn Baity, EVP, sold 26,507 with an average share price of $34.87 per share and the total transaction amounting to $924,299.09.
- On 8/9/2017 Glenn Baity, EVP, sold 14,322 with an average share price of $34.88 per share and the total transaction amounting to $499,551.36.
About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Recent Trading Activity for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Shares of ACADIA Pharmaceuticals Inc. closed the previous trading session at 13,91 −1,31 8,61 % with 5098400 shares trading hands.